A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDs

• Sponsor: Hoffmann-La Roche (Industry)
• Overall Status: Completed
• CT.gov ID: NCT00996606
• Collaborator: (none)
• Enrollment: 58
• Locations: 11
• Arm: 1
• Duration (Months): 30
• Patients Per Site: 5.3
• Patients Per Site Per Month: 0.2

Study Details

Study Description

Brief Summary

This open-label, single-arm study will evaluate the efficacy and safety of tocilizumab in combination with DMARDs in participants with moderate to severe active rheumatoid arthritis who have an inadequate response to DMARDs. Participants will receive tocilizumab as 8 milligrams per kilogram (mg/kg) via intravenous (IV) infusion every 4 weeks in addition to their current DMARD therapy.

Condition or Disease	Intervention/Treatment	Phase
Rheumatoid Arthritis	Drug: DMARDs; Drug: Tocilizumab	Phase 3

Study Design

• Study Type: Interventional
• Actual Enrollment: 58 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Open Label, Multicentric Phase IIIb Study to Evaluate the Effect of Tocilizumab in Combination With DMARDs in the Inhibition of Progression of Synovitis, Bone Marrow Edema, and Erosions Evaluated by Dedicated Magnetic Resonance Imaging (MRI) in the Hand of Patients With Rheumatoid Arthritis (RA)
• Study Start Date: Oct 1, 2009
• Actual Primary Completion Date: Apr 1, 2012
• Actual Study Completion Date: Apr 1, 2012

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Tocilizumab in Active RA Participants with active RA will receive tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions will be given from Baseline to Week 44, and participants will be assessed through Week 48.	Drug: DMARDs; Participants may continue on a stable dose of their current DMARD therapy as prescribed. The choice of DMARD is at the discretion of the treating physician and is not specified by the protocol.; Drug: Tocilizumab; Tocilizumab will be given as 8 mg/kg via IV infusion every 4 weeks for a total of 12 infusions. The maximum allowed dose is 800 mg.; Other Names: RoActemra, Actemra

Outcome Measures

Primary Outcome Measures

1. Change From Baseline to Week 4 in Synovitis of the Wrist According to Rheumatoid Arthritis Magnetic Resonance Imaging (RAMRIS) Score [Baseline and Week 4]

   Synovitis of the wrist was assessed at three sites including the radioulnar joint (RUJ), the radiocarpal joint (RCJ), and the intercarpal-carpometacarpal joints (IC-CMCJ). Global RAMRIS scores were assigned on a scale of 0 to 3 at each site, where 0 represented normal appearance with no synovial enhancement and each 1-point increase reflected one-third of the presumed maximum volume of enhancing tissue in the synovial compartment. The scores for all three sites were added to give an aggregated score of 0 to 9. Baseline absolute value (AV) and change from Baseline to Week 4 were averaged among all participants, where negative changes indicated improvement in synovitis.

2. Change From Baseline to Week 4 in Synovitis of the Wrist According to Relative Enhancement (RE) Before and After Contrast Injection [Baseline and Week 4]

   RE was calculated as [S0 minus (-) S55] divided by (÷) S0, multiplied by (×) 100 percent (%), where S0 was defined as the signal noise ratio before contrast injection, and S55 was defined as the signal noise ratio 55 seconds after injection. Signal noise ratios were measured as the ratio between the signal in the region of interest and the standard deviation of background noise. Baseline AV and change from Baseline to Week 4 were averaged among all participants, where negative changes indicated improvement in synovitis.

3. Change From Baseline to Week 4 in Synovitis of the Wrist According to Rate of Early Enhancement (REE) Per Second Before and After Contrast Injection [Baseline and Week 4]

   REE per second was calculated as [S55 - S0] ÷ [S0 × 55 seconds] × 100%, where S0 was defined as the signal noise ratio before contrast injection, and S55 was defined as the signal noise ratio 55 seconds after injection. Signal noise ratios were measured as the ratio between the signal in the region of interest and the standard deviation of background noise. Baseline AV and change from Baseline to Week 4 were averaged among all participants, where negative changes indicated improvement in synovitis.

Secondary Outcome Measures

1. Change From Baseline to Weeks 2, 12, 24, and 48 in Synovitis of the Wrist According to RAMRIS Score [Baseline and Weeks 2, 12, 24, 48]

   Synovitis of the wrist was assessed at three sites including the RUJ, the RCJ, and the IC-CMCJ. Global RAMRIS scores were assigned on a scale of 0 to 3 at each site, where 0 represented normal appearance with no synovial enhancement and each 1-point increase reflected one-third of the presumed maximum volume of enhancing tissue in the synovial compartment. The scores for all three sites were added to give an aggregated score of 0 to 9. The changes from Baseline to Weeks 2, 12, 24, and 48 were averaged among all participants, where negative changes indicated improvement in synovitis.

2. Change From Baseline to Weeks 2, 12, 24, and 48 in Synovitis of the Wrist According to RE Before and After Contrast Injection [Baseline and Weeks 2, 12, 24, 48]

   RE was calculated as [S0 - S55] ÷ S0 × 100%, where S0 was defined as the signal noise ratio before contrast injection, and S55 was defined as the signal noise ratio 55 seconds after injection. Signal noise ratios were measured as the ratio between the signal in the region of interest and the standard deviation of background noise. The changes from Baseline to Weeks 2, 12, 24, and 48 were averaged among all participants, where negative changes indicated improvement in synovitis.

3. Change From Baseline to Weeks 2, 12, 24, and 48 in Synovitis of the Wrist According to REE Per Second Before and After Contrast Injection [Baseline and Weeks 2, 12, 24, 48]

   REE per second was calculated as [S55 - S0] ÷ [S0 × 55 seconds] × 100%, where S0 was defined as the signal noise ratio before contrast injection, and S55 was defined as the signal noise ratio 55 seconds after injection. Signal noise ratios were measured as the ratio between the signal in the region of interest and the standard deviation of background noise. The changes from Baseline to Weeks 2, 12, 24, and 48 were averaged among all participants, where negative changes indicated improvement in synovitis.

4. Change From Baseline to Weeks 2, 4, 12, 24, and 48 in Synovitis of the Wrist and Metacarpo-Phalangeal (MCP) Joints According to Modified RAMRIS Score [Baseline and Weeks 2, 4, 12, 24, 48]

   Synovitis of the wrist was assessed at three sites including the RUJ, the RCJ, and the IC-CMCJ. Global RAMRIS scores were assigned on a scale of 0 to 3 at each site, where 0 represented normal appearance with no synovial enhancement and each 1-point increase reflected one-third of the presumed maximum volume of enhancing tissue in the synovial compartment. The scores for all three sites were added to give an aggregated score of 0 to 9. Synovitis of MCP joints was determined on the basis of Short Inversion Time Inversion Recovery (STIR) sequence evaluation with modification of the RAMRIS score. Four MCP joint compartments were each assessed 0 to 3, so the aggregated MCP joint score ranged from 0 to 12. Combined synovitis in wrist and MCP joints was determined on the basis of STIR sequences to produce overall score from 0 to 21. Baseline AV and changes from Baseline to Weeks 2, 4, 12, 24, 48 were averaged among all participants, where negative changes indicated improvement in synovitis.

5. Change From Baseline to Weeks 2, 4, 12, 24, and 48 in Number of Bones With Erosion in the Wrist and MCP Joints [Baseline and Weeks 2, 4, 12, 24, 48]

   Erosion was evaluated at 15 sites in the wrist and 8 sites in the MCP joints. Bone erosion was scored on a scale of 0 to 10, where 0 represented no bone erosion and each 1-point increase reflected up to a 10% increase in extent of erosion. The number of bones with erosion was taken as the count of joints with a bone erosion score greater than or equal to (≥) 1. Baseline AV and changes from Baseline to Weeks 2, 4, 12, 24, and 48 were averaged among all participants, where negative changes indicated improvement in erosion.

6. Change From Baseline to Weeks 2, 4, 12, 24, and 48 in Erosion of the Wrist and MCP Joints According to RAMRIS Score [Baseline and Weeks 2, 4, 12, 24, 48]

   Erosion was evaluated at 15 sites in the wrist and 8 sites in the MCP joints. Bone erosion was scored on a scale of 0 to 10, where 0 represented no bone erosion and each 1-point increase reflected up to 10% increase in extent of erosion. Global RAMRIS scores were calculated as the sum of all joint sites for the wrist (range, 0 to 150) and MCP joints (range, 0 to 80). Aggregate wrist and MCP joint scores could range from 0 to 230 points. Baseline AV and changes from Baseline to Weeks 2, 4, 12, 24, and 48 were averaged among all participants, where negative changes indicated improvement in erosion.

7. Change From Baseline to Weeks 2, 4, 12, 24, and 48 in Number of Bones With Bone Marrow Edema in the Wrist and MCP Joints [Baseline and Weeks 2, 4, 12, 24, 48]

   Edema was evaluated at 15 sites in the wrist and 8 sites in the MCP joints. Bone edema was scored on a scale of 0 to 3, where 0 represented no bone edema and each 1-point increase reflected one-third increase in extent of edema. The number of bones with edema was taken as the count of joints with a bone edema score greater than or equal to (≥) 1. Baseline AV and changes from Baseline to Weeks 2, 4, 12, 24, and 48 were averaged among all participants, where negative changes indicated improvement in edema.

8. Change From Baseline to Weeks 2, 4, 12, 24, and 48 in Bone Marrow Edema of the Wrist and MCP Joints According to RAMRIS Score [Baseline and Weeks 2, 4, 12, 24, 48]

   Edema was evaluated at 15 sites in the wrist and 8 sites in the MCP joints. Bone edema was scored on a scale of 0 to 3, where 0 represented no bone edema and each 1-point increase reflected one-third increase in extent of edema. Global RAMRIS scores were calculated as the sum of all joint sites for the wrist (range, 0 to 45) and MCP joints (range, 0 to 24). Aggregate wrist and MCP joint scores could range from 0 to 69 points. Baseline AV and changes from Baseline to Weeks 2, 4, 12, 24, and 48 were averaged among all participants, where negative changes indicated improvement in edema.

9. Change From Baseline to Weeks 24 and 48 in Total Modified Sharp Score (TMSS), Erosion Score (ES), and Joint Space Narrowing Score (JSNS) [Baseline and Weeks 24, 48]

   The TMSS was calculated as the sum of ES and JSNS and ranged from 0 to 202. The ES was taken as the sum of joint scores collected for 14 joints in each hand (individually scored from 0 to 7) and ranged from 0 to 98 for both hands. The JSNS was the sum of joint scores collected for 13 joints in each hand (individually scored from 0 to 8) and ranged from 0 to 104 for both hands. Scores of 0 reflected no change, while higher scores reflected increased disease activity. Baseline AV and changes from Baseline to Weeks 24 and 48 were averaged among all participants, where negative changes indicated improvement in disease activity.

10. Change From Baseline to Weeks 2, 4, 12, 24, and 48 in Ritchie Articular Index Score [Baseline and Weeks 2, 4, 12, 24, 48]

    The Ritchie Articular Index was scored on a scale of 0 to 3, according to the grades of tenderness in each of 26 assessed joints. The total score was taken as the sum of joint scores and ranged from 0 to 78. Scores of 0 reflected no tenderness, while higher scores reflected increased tenderness. Baseline AV and changes from Baseline to Weeks 2, 4, 12, 24, and 48 were averaged among all participants, where negative changes indicated improvement in joint tenderness.

11. Change From Baseline to Weeks 2, 4, 12, 24, and 48 in Perceived Pain According to Visual Analog Scale (VAS) Score [Baseline and Weeks 2, 4, 12, 24, 48]

    Perceived pain was assessed on a 0- to 100-millimeter (mm) VAS, where the distance from 0 mm represented the participant's self evaluation of pain (0 mm = no pain, 100 mm = maximum pain). Baseline AV and changes from Baseline to Weeks 2, 4, 12, 24, and 48 were averaged among all participants, where negative changes indicated a decrease in perceived pain.

12. Change From Baseline to Weeks 2, 4, 12, 24, and 48 in Perceived General Health According to VAS Score [Baseline and Weeks 2, 4, 12, 24, 48]

    Global assessment of disease activity was performed using a 0- to 100-mm VAS, where the distance from 0 mm represented the investigator's evaluation or the participant's self evaluation of disease activity (0 mm = no disease activity, 100 mm = maximum disease activity). Baseline AV and changes from Baseline to Weeks 2, 4, 12, 24, and 48 were averaged among all participants, where negative changes indicated improvement in disease activity.

13. Change From Baseline to Weeks 2, 4, 12, 24, and 48 in Health Assessment Questionnaire Disability Index (HAQ-DI) Score [Baseline and Weeks 2, 4, 12, 24, 48]

    The HAQ-DI assessed 20 items in eight functional activity domains including dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Each item was scored on a scale of 0 to 3, where 0 represented activities performed without difficulty and 3 represented inability to perform activities alone. The total score was calculated as an average of all item scores, and thus also ranged from 0 to 3. Baseline AV and changes from Baseline to Weeks 2, 4, 12, 24, and 48 were averaged among all participants, where negative changes indicated an increase in ability to perform activities independently.

14. Change From Baseline to Weeks 2, 4, 12, 24, and 48 in Disease Activity Score of 28 Joints (DAS28) Score [Baseline and Weeks 2, 4, 12, 24, 48]

    The DAS28 was derived from assessments of C-reactive protein (CRP), tender joint count (TJC), swollen joint count (SJC), and general health according to 100-mm VAS. DAS28 scores were calculated as [0.56 × square root of TJC] plus (+) [0.28 × square root of SJC] + [0.36 × natural log (CRP + 1)] + [0.014 × VAS] + 0.96. TJC was defined as the number of painful joints and SJC was defined as the number of swollen joints, each assessed on 28 joints. CRP was measured in milligrams per deciliter (mg/dL). DAS28 scores could range from 0 to 10, where higher scores represented higher disease activity. Baseline AV and changes from Baseline to Weeks 2, 4, 12, 24, and 48 were averaged among all participants, where negative changes indicated an improvement in disease activity.

15. Change From Baseline to Weeks 2, 4, 12, 24, and 48 in Vascular Endothelial Growth Factor (VEGF) Concentration [Baseline and Weeks 2, 4, 12, 24, 48]

    Level of VEGF was measured in picograms per milliliter (pg/mL). Baseline AV and changes from Baseline to Weeks 2, 4, 12, 24, and 48 were averaged among all participants.

16. Change From Baseline to Weeks 2, 4, 12, 24, and 48 in Erythrocyte Sedimentation Rate (ESR) [Baseline and Weeks 2, 4, 12, 24, 48]

    ESR was measured in millimeters per hour (mm/h). Baseline AV and changes from Baseline to Weeks 2, 4, 12, 24, and 48 were averaged among all participants.

17. Change From Baseline to Weeks 2, 4, 12, 24, and 48 in High-Sensitivity C-Reactive Protein (hsCRP) Concentration [Baseline and Weeks 2, 4, 12, 24, 48]

    Level of hsCRP was measured in mg/dL. Baseline AV and changes from Baseline to Weeks 2, 4, 12, 24, and 48 were averaged among all participants.

18. Change From Baseline to Weeks 2 and 4 in Soluble Interleukin-6 Receptor (sIL6R) Level [Baseline and Weeks 2, 4]

    Level of sIL6R was measured in pg/mL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

19. Change From Baseline to Weeks 2 and 4 in Messenger Ribonucleic Acid (mRNA) for Interleukin (IL)-17 (2^Delta Cycle Threshold [ΔCt]) Level [Baseline and Weeks 2, 4]

    Level of mRNA for IL-17 (2^ΔCt) was quantified by polymerase chain reaction (PCR). Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

20. Change From Baseline to Weeks 2 and 4 in mRNA for IL-23 Receptor (2^ΔCt) Level [Baseline and Weeks 2, 4]

    Level of mRNA for IL-23 receptor (2^ΔCt) was quantified by PCR. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

21. Change From Baseline to Weeks 2 and 4 in mRNA for RAR-Related Orphan Receptor (ROR)-γT (2^ΔCt) Level [Baseline and Weeks 2, 4]

    Level of ROR-γT (2^ΔCt) was quantified by PCR. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

22. Change From Baseline to Weeks 2 and 4 in mRNA for Forkhead Box Protein (FOXP) 3 (2^ΔCt) Level [Baseline and Weeks 2, 4]

    Level of mRNA for FOXP3 (2^ΔCt) was quantified by PCR. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

23. Change From Baseline to Weeks 2 and 4 in Cluster of Differentiation (CD) 4-Positive Cells as a Percentage of Peripheral Blood Mononuclear Cells (PBMCs) [Baseline and Weeks 2, 4]

    The intensity of CD4-positive cell infiltration was expressed as the percentage of PBMCs. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

24. Change From Baseline to Weeks 2 and 4 in CD4 Mean Intensity of Fluorescence [Baseline and Weeks 2, 4]

    The mean fluorescence intensity of CD4-positive cells was measured by flow cytometry. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

25. Change From Baseline to Weeks 2 and 4 in CD25-Positive Cells as a Percentage of PBMCs [Baseline and Weeks 2, 4]

    The intensity of CD25-positive cell infiltration was expressed as the percentage of PBMCs. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

26. Change From Baseline to Weeks 2 and 4 in CD25 Mean Intensity of Fluorescence [Baseline and Weeks 2, 4]

    The mean fluorescence intensity of CD25-positive cells was measured by flow cytometry. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

27. Change From Baseline to Weeks 2 and 4 in CD45 "RO" Isoform (RO)-Positive Cells as a Percentage of PBMCs [Baseline and Weeks 2, 4]

    The intensity of CD45RO-positive cell infiltration was expressed as the percentage of PBMCs. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

28. Change From Baseline to Weeks 2 and 4 in CD45RO Mean Intensity of Fluorescence [Baseline and Weeks 2, 4]

    The mean fluorescence intensity of CD45RO-positive cells was measured by flow cytometry. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

29. Change From Baseline to Weeks 2 and 4 in Cysteine-Cysteine Chemokine Receptor (CCR) 6-Positive Cells as a Percentage of PBMCs [Baseline and Weeks 2, 4]

    The intensity of CCR6-positive cell infiltration was expressed as the percentage of PBMCs. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

30. Change From Baseline to Weeks 2 and 4 in CCR6 Mean Intensity of Fluorescence [Baseline and Weeks 2, 4]

    The mean fluorescence intensity of CCR6-positive cells was measured by flow cytometry. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

31. Change From Baseline to Weeks 2 and 4 in CCR4-Positive Cells as a Percentage of PBMCs [Baseline and Weeks 2, 4]

    The intensity of CCR4-positive cell infiltration was expressed as the percentage of PBMCs. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

32. Change From Baseline to Weeks 2 and 4 in CCR4 Mean Intensity of Fluorescence [Baseline and Weeks 2, 4]

    The mean fluorescence intensity of CCR4-positive cells was measured by flow cytometry. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

33. Change From Baseline to Weeks 2 and 4 in IL-23 Receptor p19 Subunit (IL-23Rp19)-Positive Cells as a Percentage of PBMCs [Baseline and Weeks 2, 4]

    The intensity of IL-23Rp19-positive cell infiltration was expressed as the percentage of PBMCs. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

34. Change From Baseline to Weeks 2 and 4 in IL-23Rp19 Mean Intensity of Fluorescence [Baseline and Weeks 2, 4]

    The mean fluorescence intensity of IL-23Rp19-positive cells was measured by flow cytometry. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

35. Change From Baseline to Weeks 2 and 4 in Regulatory T (Treg) Cells as a Percentage of PBMCs [Baseline and Weeks 2, 4]

    The intensity of Treg cell infiltration was expressed as the percentage of PBMCs. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

36. Change From Baseline to Weeks 2 and 4 in Treg Cells as a Percentage of T Cells [Baseline and Weeks 2, 4]

    The intensity of Treg cell infiltration was expressed as the percentage of T cells. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

37. Change From Baseline to Weeks 2 and 4 in Treg Cell Level [Baseline and Weeks 2, 4]

    The absolute number of Treg cells was expressed as cells per microliter (cells/mcL). Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

38. Change From Baseline to Weeks 2 and 4 in Helper T (Th) 17 Cells as a Percentage of PBMCs [Baseline and Weeks 2, 4]

    The intensity of Th17 cell infiltration was expressed as the percentage of PBMCs. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

39. Change From Baseline to Weeks 2 and 4 in Th17 Cells as a Percentage of T Cells [Baseline and Weeks 2, 4]

    The intensity of Th17 cell infiltration was expressed as the percentage of T cells. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

40. Change From Baseline to Weeks 2 and 4 in Th17 Cell Level [Baseline and Weeks 2, 4]

    The absolute number of Th17 cells was expressed as cells/mcL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

41. Change From Baseline to Weeks 2 and 4 in CD19-Positive Cells as a Percentage of PBMCs [Baseline and Weeks 2, 4]

    The intensity of CD19-positive cell infiltration was expressed as the percentage of PBMCs. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

42. Change From Baseline to Weeks 2 and 4 in CD19 Mean Intensity of Fluorescence [Baseline and Weeks 2, 4]

    The mean fluorescence intensity of CD19-positive cells was measured by flow cytometry. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

43. Change From Baseline to Weeks 2 and 4 in CD24-Positive Cells as a Percentage of PBMCs [Baseline and Weeks 2, 4]

    The intensity of CD24-positive cell infiltration was expressed as the percentage of PBMCs. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

44. Change From Baseline to Weeks 2 and 4 in CD24 Mean Intensity of Fluorescence [Baseline and Weeks 2, 4]

    The mean fluorescence intensity of CD24-positive cells was measured by flow cytometry. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

45. Change From Baseline to Weeks 2 and 4 in CD27-Positive Cells as a Percentage of PBMCs [Baseline and Weeks 2, 4]

    The intensity of CD27-positive cell infiltration was expressed as the percentage of PBMCs. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

46. Change From Baseline to Weeks 2 and 4 in CD27 Mean Intensity of Fluorescence [Baseline and Weeks 2, 4]

    The mean fluorescence intensity of CD27-positive cells was measured by flow cytometry. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

47. Change From Baseline to Weeks 2 and 4 in CD38-Positive Cells as a Percentage of PBMCs [Baseline and Weeks 2, 4]

    The intensity of CD38-positive cell infiltration was expressed as the percentage of PBMCs. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

48. Change From Baseline to Weeks 2 and 4 in CD38 Mean Intensity of Fluorescence [Baseline and Weeks 2, 4]

    The mean fluorescence intensity of CD38-positive cells was measured by flow cytometry. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

49. Change From Baseline to Weeks 2 and 4 in Immunoglobulin (Ig) M-Positive Cells as a Percentage of PBMCs [Baseline and Weeks 2, 4]

    The intensity of IgM-positive cell infiltration was expressed as the percentage of PBMCs. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

50. Change From Baseline to Weeks 2 and 4 in IgM Mean Intensity of Fluorescence [Baseline and Weeks 2, 4]

    The mean fluorescence intensity of IgM-positive cells was measured by flow cytometry. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

51. Change From Baseline to Weeks 2 and 4 in Mature B Cells as a Percentage of PBMCs [Baseline and Weeks 2, 4]

    The intensity of mature B cell infiltration was expressed as the percentage of PBMCs. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

52. Change From Baseline to Weeks 2 and 4 in Mature B Cells as a Percentage of B Cells [Baseline and Weeks 2, 4]

    The intensity of mature B cell infiltration was expressed as the percentage of B cells. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

53. Change From Baseline to Week 4 in Mature B Cell Level [Baseline and Week 4]

    The absolute number of mature B cells was expressed as cells/mcL. Baseline AV and change from Baseline to Week 4 were averaged among all participants.

54. Change From Baseline to Weeks 2 and 4 in Memory B Cells as a Percentage of PBMCs [Baseline and Weeks 2, 4]

    The intensity of memory B cell infiltration was expressed as the percentage of PBMCs. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

55. Change From Baseline to Weeks 2 and 4 in Memory B Cells as a Percentage of B Cells [Baseline and Weeks 2, 4]

    The intensity of memory B cell infiltration was expressed as the percentage of B cells. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

56. Change From Baseline to Week 4 in Memory B Cell Level [Baseline and Week 4]

    The absolute number of memory B cells was expressed as cells/mcL. Baseline AV and change from Baseline to Week 4 were averaged among all participants.

57. Change From Baseline to Weeks 2 and 4 in Transitional B Cells as a Percentage of PBMCs [Baseline and Weeks 2, 4]

    The intensity of transitional B cell infiltration was expressed as the percentage of PBMCs. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

58. Change From Baseline to Weeks 2 and 4 in Transitional B Cells as a Percentage of B Cells [Baseline and Weeks 2, 4]

    The intensity of transitional B cell infiltration was expressed as the percentage of B cells. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

59. Change From Baseline to Week 4 in Transitional B Cell Level [Baseline and Week 4]

    The absolute number of transitional B cells was expressed as cells/mcL. Baseline AV and change from Baseline to Week 4 were averaged among all participants.

60. Change From Baseline to Weeks 2 and 4 in Plasma B Cells as a Percentage of PBMCs [Baseline and Weeks 2, 4]

    The intensity of plasma B cell infiltration was expressed as the percentage of PBMCs. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

61. Change From Baseline to Weeks 2 and 4 in Plasma B Cells as a Percentage of B Cells [Baseline and Weeks 2, 4]

    The intensity of plasma B cell infiltration was expressed as the percentage of B cells. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

62. Change From Baseline to Week 4 in Plasma B Cell Level [Baseline and Week 4]

    The absolute number of plasma B cells was expressed as cells/mcL. Baseline AV and change from Baseline to Week 4 were averaged among all participants.

63. Change From Baseline to Weeks 2 and 4 in Th17 Cysteine-Cysteine Chemokine Ligand (CCL) 20 Level [Baseline and Weeks 2, 4]

    Level of Th17CCL20 was measured in pg/mL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

64. Change From Baseline to Weeks 2 and 4 in Th17CCL17 Level [Baseline and Weeks 2, 4]

    Level of Th17CCL20 was measured in pg/mL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

65. Change From Baseline to Weeks 2 and 4 in B Cell-Attracting Chemokine (BCA) Level [Baseline and Weeks 2, 4]

    Level of BCA was measured in pg/mL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

66. Change From Baseline to Weeks 2 and 4 in Stromal Cell-Derived Factor (SDF) 1 Level [Baseline and Weeks 2, 4]

    Level of SDF1 was measured in pg/mL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

67. Change From Baseline to Weeks 2 and 4 in B Cell-Activating Factor (BAFF) Level [Baseline and Weeks 2, 4]

    Level of BAFF was measured in pg/mL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

68. Change From Baseline to Weeks 2 and 4 in A Proliferation-Inducing Ligand (APRIL) Level [Baseline and Weeks 2, 4]

    Level of APRIL was measured in pg/mL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

69. Change From Baseline to Weeks 2 and 4 in Tumor Necrosis Factor (TNF)-α Level [Baseline and Weeks 2, 4]

    Level of TNF-α was measured in pg/mL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

70. Change From Baseline to Weeks 2 and 4 in IL-1β Level [Baseline and Weeks 2, 4]

    Level of IL-1β was measured in pg/mL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

71. Change From Baseline to Weeks 2 and 4 in IL-17 Level [Baseline and Weeks 2, 4]

    Level of IL-17 was measured in pg/mL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

72. Change From Baseline to Weeks 2 and 4 in Monocyte Chemoattractant Protein (MCaP)-1 Level [Baseline and Weeks 2, 4]

    Level of MCaP-1 was measured in pg/mL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

73. Change From Baseline to Weeks 2 and 4 in Osteocalcin Level [Baseline and Weeks 2, 4]

    Level of osteocalcin was measured in pg/mL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

74. Change From Baseline to Weeks 2 and 4 in Type I Collagen N-Propeptide Level [Baseline and Weeks 2, 4]

    Level of Type I collagen N-propeptide was measured in pg/mL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

75. Change From Baseline to Weeks 2 and 4 in C-Terminal Telopeptide (CTX)-1 Level [Baseline and Weeks 2, 4]

    Level of CTX-1 was measured in pg/mL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

76. Change From Baseline to Weeks 2 and 4 in Type I Collagen C-Terminal Telopeptide (ICTP) Level [Baseline and Weeks 2, 4]

    Level of ICTP was measured in pg/mL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

77. Change From Baseline to Weeks 2 and 4 in Type II Collagen N-Propeptide (PIIANP) Level [Baseline and Weeks 2, 4]

    Level of PIIANP was measured in pg/mL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

78. Change From Baseline to Weeks 2 and 4 in Type II Collagen Helical Peptide (HELIX-II) Level [Baseline and Weeks 2, 4]

    Level of HELIX-II was measured in pg/mL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.

79. Change From Baseline to Weeks 2, 4, 12, 24, and 48 in Hemoglobin (Hb) Concentration [Baseline and Weeks 2, 4, 12, 24, 48]

    Level of Hb was measured in grams per liter (g/L). Baseline AV and changes from Baseline to Weeks 2, 4, 12, 24, and 48 were averaged among all participants.

80. Change From Baseline to Day 2 and Weeks 2 and 4 in Soluble Transferrin Receptor (STR) Concentration [Baseline; Day 2; and Weeks 2, 4]

    Level of STR was measured in pg/mL. Baseline AV and changes from Baseline to Day 2 and Weeks 2 and 4 were averaged among all participants.

81. Change From Baseline to Week 48 in Initial Rate of Enhancement (IRE) by DYNAMIKA Software Analysis [Baseline and Week 48]

    IRE was approximated by parametric mapping via DYNAMIKA software and expressed as change in relative signal intensity per second (ΔI/sec). The mean of three different slices was used in the determination of IRE. Each slice consisted of a two-dimensional (2D) sequence of images acquired from the same physical location at different time instances. Baseline AV and change from Baseline to Week 48 were averaged among all participants.

82. Change From Baseline to Week 48 in Maximum Enhancement (ME) by DYNAMIKA Software Analysis [Baseline and Week 48]

    ME was approximated by parametric mapping via DYNAMIKA software and expressed as ratio of signal enhancement before and after contrast injection. The mean of three different slices was used in the determination of ME. Each slice consisted of a 2D sequence of images acquired from the same physical location at different time instances. Baseline AV and change from Baseline to Week 48 were averaged among all participants.

83. Change From Baseline to Week 48 in Number of Enhancing Voxels (Ntotal) by DYNAMIKA Software Analysis [Baseline and Week 48]

    Ntotal was approximated using DYNAMIKA software. The sum of three different slices was used in the determination of Ntotal. Each slice consisted of a 2D sequence of images acquired from the same physical location at different time instances. Baseline AV and change from Baseline to Week 48 were averaged among all participants.

84. Change From Baseline to Week 48 in Number of Persistent Enhancing Voxels (Npersistent) by DYNAMIKA Software Analysis [Baseline and Week 48]

    Npersistent was approximated using DYNAMIKA software. The sum of three different slices was used in the determination of Npersistent. Each slice consisted of a 2D sequence of images acquired from the same physical location at different time instances. Baseline AV and change from Baseline to Week 48 were averaged among all participants.

85. Change From Baseline to Week 48 in Number of Plateau Enhancing Voxels (Nplateau) by DYNAMIKA Software Analysis [Baseline and Week 48]

    Nplateau was approximated using DYNAMIKA software. The sum of three different slices was used in the determination of Nplateau. Each slice consisted of a 2D sequence of images acquired from the same physical location at different time instances. Baseline AV and change from Baseline to Week 48 were averaged among all participants.

86. Change From Baseline to Week 48 in Number of Washout Enhancing Voxels (Nwashout) by DYNAMIKA Software Analysis [Baseline and Week 48]

    Nwashout was approximated using DYNAMIKA software. The sum of three different slices was used in the determination of Nwashout. Each slice consisted of a 2D sequence of images acquired from the same physical location at different time instances. Baseline AV and change from Baseline to Week 48 were averaged among all participants.

87. Change From Baseline to Week 48 in Ntotal×IRE by DYNAMIKA Software Analysis [Baseline and Week 48]

    Ntotal and IRE were approximated using DYNAMIKA software. The sum of three different slices was used in the determination of Ntotal. The mean of three different slices was used in the determination of IRE. Each slice consisted of a 2D sequence of images acquired from the same physical location at different time instances. Function of Ntotal×IRE was expressed as voxels times change in relative intensity per second (v*ΔI/sec). Baseline AV and change from Baseline to Week 48 were averaged among all participants.

88. Change From Baseline to Week 48 in Ntotal×ME by DYNAMIKA Software Analysis [Baseline and Week 48]

    Ntotal and ME were approximated using DYNAMIKA software. The sum of three different slices was used in the determination of Ntotal. The mean of three different slices was used in the determination of ME. Each slice consisted of a 2D sequence of images acquired from the same physical location at different time instances. Function of NtotalME was expressed as voxels times ratio of signal intensity before and after contrast injection (v*ratio). Baseline AV and change from Baseline to Week 48 were averaged among all participants.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Moderate to severe active RA of ≥6 months duration

• DAS28 >3.2

• Inadequate response to a stable dose of non-biologic DMARD for ≥2 months

• Those receiving oral corticosteroids must have been at stable dose for ≥25 days in the 28 days prior to first study treatment

Exclusion Criteria:

• Rheumatic autoimmune disease other than RA

• History of or current inflammatory joint disease other than RA

• Previous treatment with alkylating agents or total lymphoid irradiation

• Intra-articular or parenteral corticosteroids within 6 weeks prior to Baseline

• Previous treatment with any cell-depleting therapies

• American College of Rheumatology (ACR) Functional Class IV

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1		Coppito	Abruzzo	Italy	67100
2		Napoli	Campania	Italy	80131
3		Roma	Lazio	Italy	00161
4		Genova	Liguria	Italy	16132
5		Milano	Lombardia	Italy	20122
6		Milano	Lombardia	Italy	20157
7		Pavia	Lombardia	Italy	27100
8		Palermo	Sicilia	Italy	90127
9		Pisa	Toscana	Italy	56100
10		Cona (Ferrara)	Veneto	Italy	44124
11		Padova	Veneto	Italy	35128

Sponsors and Collaborators

• Hoffmann-La Roche

Investigators

• Study Director: Clinical Trials, Hoffmann-La Roche

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Hoffmann-La Roche
• ClinicalTrials.gov Identifier: NCT00996606
• Other Study ID Numbers: ML22413; 2009-012185-32
• First Posted: Oct 16, 2009
• Last Update Posted: Jun 19, 2017
• Last Verified: May 1, 2017

• Additional relevant MeSH terms: Arthritis; Arthritis, Rheumatoid

Study Results

Participant Flow

Arm/Group Title	Tocilizumab in Active Rheumatoid Arthritis (RA)
Arm/Group Description	Participants with active RA received tocilizumab as 8 milligrams per kilogram (mg/kg) via intravenous (IV) infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Period Title: Overall Study
STARTED	58
COMPLETED	50
NOT COMPLETED	8

Baseline Characteristics

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Overall Participants	58
Age (years) [Mean (Standard Deviation) ]
Mean (Standard Deviation) [years]	51.5 (13.0)
Sex: Female, Male (Count of Participants)
Female	45 77.6%
Male	13 22.4%

Outcome Measures

1. Primary Outcome

Title	Change From Baseline to Week 4 in Synovitis of the Wrist According to Rheumatoid Arthritis Magnetic Resonance Imaging (RAMRIS) Score
Description	Synovitis of the wrist was assessed at three sites including the radioulnar joint (RUJ), the radiocarpal joint (RCJ), and the intercarpal-carpometacarpal joints (IC-CMCJ). Global RAMRIS scores were assigned on a scale of 0 to 3 at each site, where 0 represented normal appearance with no synovial enhancement and each 1-point increase reflected one-third of the presumed maximum volume of enhancing tissue in the synovial compartment. The scores for all three sites were added to give an aggregated score of 0 to 9. Baseline absolute value (AV) and change from Baseline to Week 4 were averaged among all participants, where negative changes indicated improvement in synovitis.
Time Frame	Baseline and Week 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	55
Baseline AV (n=55)	5.78 (2.72)
Week 4 (n=49)	-0.88 (1.56)

2. Primary Outcome

Title	Change From Baseline to Week 4 in Synovitis of the Wrist According to Relative Enhancement (RE) Before and After Contrast Injection
Description	RE was calculated as [S0 minus (-) S55] divided by (÷) S0, multiplied by (×) 100 percent (%), where S0 was defined as the signal noise ratio before contrast injection, and S55 was defined as the signal noise ratio 55 seconds after injection. Signal noise ratios were measured as the ratio between the signal in the region of interest and the standard deviation of background noise. Baseline AV and change from Baseline to Week 4 were averaged among all participants, where negative changes indicated improvement in synovitis.
Time Frame	Baseline and Week 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	54
Baseline AV (n=54)	99.25 (57.85)
Week 4 (n=45)	-0.48 (47.85)

3. Primary Outcome

Title	Change From Baseline to Week 4 in Synovitis of the Wrist According to Rate of Early Enhancement (REE) Per Second Before and After Contrast Injection
Description	REE per second was calculated as [S55 - S0] ÷ [S0 × 55 seconds] × 100%, where S0 was defined as the signal noise ratio before contrast injection, and S55 was defined as the signal noise ratio 55 seconds after injection. Signal noise ratios were measured as the ratio between the signal in the region of interest and the standard deviation of background noise. Baseline AV and change from Baseline to Week 4 were averaged among all participants, where negative changes indicated improvement in synovitis.
Time Frame	Baseline and Week 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	54
Baseline AV (n=54)	1.19 (1.04)
Week 4 (n=45)	-0.10 (0.86)

4. Secondary Outcome

Title	Change From Baseline to Weeks 2, 12, 24, and 48 in Synovitis of the Wrist According to RAMRIS Score
Description	Synovitis of the wrist was assessed at three sites including the RUJ, the RCJ, and the IC-CMCJ. Global RAMRIS scores were assigned on a scale of 0 to 3 at each site, where 0 represented normal appearance with no synovial enhancement and each 1-point increase reflected one-third of the presumed maximum volume of enhancing tissue in the synovial compartment. The scores for all three sites were added to give an aggregated score of 0 to 9. The changes from Baseline to Weeks 2, 12, 24, and 48 were averaged among all participants, where negative changes indicated improvement in synovitis.
Time Frame	Baseline and Weeks 2, 12, 24, 48

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	50
Week 2 (n=45)	-0.44 (1.03)
Week 12 (n=50)	-1.28 (1.96)
Week 24 (n=49)	-1.94 (2.34)
Week 48 (n=47)	-1.60 (2.42)

5. Secondary Outcome

Title	Change From Baseline to Weeks 2, 12, 24, and 48 in Synovitis of the Wrist According to RE Before and After Contrast Injection
Description	RE was calculated as [S0 - S55] ÷ S0 × 100%, where S0 was defined as the signal noise ratio before contrast injection, and S55 was defined as the signal noise ratio 55 seconds after injection. Signal noise ratios were measured as the ratio between the signal in the region of interest and the standard deviation of background noise. The changes from Baseline to Weeks 2, 12, 24, and 48 were averaged among all participants, where negative changes indicated improvement in synovitis.
Time Frame	Baseline and Weeks 2, 12, 24, 48

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	49
Week 2 (n=44)	5.80 (46.14)
Week 12 (n=49)	-9.27 (50.07)
Week 24 (n=48)	-26.48 (57.99)
Week 48 (n=45)	-19.74 (74.08)

6. Secondary Outcome

Title	Change From Baseline to Weeks 2, 12, 24, and 48 in Synovitis of the Wrist According to REE Per Second Before and After Contrast Injection
Description	REE per second was calculated as [S55 - S0] ÷ [S0 × 55 seconds] × 100%, where S0 was defined as the signal noise ratio before contrast injection, and S55 was defined as the signal noise ratio 55 seconds after injection. Signal noise ratios were measured as the ratio between the signal in the region of interest and the standard deviation of background noise. The changes from Baseline to Weeks 2, 12, 24, and 48 were averaged among all participants, where negative changes indicated improvement in synovitis.
Time Frame	Baseline and Weeks 2, 12, 24, 48

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	49
Week 2 (n=44)	-0.04 (1.11)
Week 12 (n=49)	-0.48 (0.96)
Week 24 (n=48)	-0.57 (0.87)
Week 48 (n=45)	-0.66 (1.24)

7. Secondary Outcome

Title	Change From Baseline to Weeks 2, 4, 12, 24, and 48 in Synovitis of the Wrist and Metacarpo-Phalangeal (MCP) Joints According to Modified RAMRIS Score
Description	Synovitis of the wrist was assessed at three sites including the RUJ, the RCJ, and the IC-CMCJ. Global RAMRIS scores were assigned on a scale of 0 to 3 at each site, where 0 represented normal appearance with no synovial enhancement and each 1-point increase reflected one-third of the presumed maximum volume of enhancing tissue in the synovial compartment. The scores for all three sites were added to give an aggregated score of 0 to 9. Synovitis of MCP joints was determined on the basis of Short Inversion Time Inversion Recovery (STIR) sequence evaluation with modification of the RAMRIS score. Four MCP joint compartments were each assessed 0 to 3, so the aggregated MCP joint score ranged from 0 to 12. Combined synovitis in wrist and MCP joints was determined on the basis of STIR sequences to produce overall score from 0 to 21. Baseline AV and changes from Baseline to Weeks 2, 4, 12, 24, 48 were averaged among all participants, where negative changes indicated improvement in synovitis.
Time Frame	Baseline and Weeks 2, 4, 12, 24, 48

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	55
Wrist Global Score, Baseline AV (n=55)	5.04 (2.24)
Wrist Global Score, Week 2 (n=45)	-0.02 (1.70)
Wrist Global Score, Week 4 (n=50)	-0.20 (1.50)
Wrist Global Score, Week 12 (n=51)	-0.47 (2.07)
Wrist Global Score, Week 24 (n=50)	-1.06 (2.11)
Wrist Global Score, Week 48 (n=47)	-1.23 (2.28)
Wrist Distal RUJ Score, Baseline AV (n=53)	1.62 (0.95)
Wrist Distal RUJ Score, Week 2 (n=43)	-0.09 (0.78)
Wrist Distal RUJ Score, Week 4 (n=48)	-0.15 (0.62)
Wrist Distal RUJ Score, Week 12 (n=48)	-0.21 (0.87)
Wrist Distal RUJ Score, Week 24 (n=48)	-0.44 (0.74)
Wrist Distal RUJ Score, Week 48 (n=45)	-0.58 (0.94)
Wrist Distal RCJ Score, Baseline AV (n=55)	1.73 (0.78)
Wrist Distal RCJ Score, Week 2 (n=45)	0.11 (0.80)
Wrist Distal RCJ Score, Week 4 (n=50)	-0.06 (0.62)
Wrist Distal RCJ Score, Week 12 (n=51)	-0.12 (0.77)
Wrist Distal RCJ Score, Week 24 (n=50)	-0.30 (0.91)
Wrist Distal RCJ Score, Week 48 (n=47)	-0.38 (0.92)
Wrist IC-CMCJ Score, Baseline AV (n=55)	1.75 (0.89)
Wrist IC-CMCJ Score, Week 2 (n=44)	0.00 (0.72)
Wrist IC-CMCJ Score, Week 4 (n=50)	0.00 (0.70)
Wrist IC-CMCJ Score, Week 12 (n=51)	-0.22 (0.88)
Wrist IC-CMCJ Score, Week 24 (n=50)	-0.40 (0.88)
Wrist IC-CMCJ Score, Week 48 (n=47)	-0.34 (0.96)
MCP STIR Joint Score, Baseline AV (n=54)	4.57 (3.10)
MCP STIR Joint Score, Week 2 (n=40)	-0.13 (1.76)
MCP STIR Joint Score, Week 4 (n=47)	-0.53 (1.90)
MCP STIR Joint Score, Week 12 (n=45)	-0.53 (2.07)
MCP STIR Joint Score, Week 24 (n=46)	-1.02 (2.24)
MCP STIR Joint Score, Week 48 (n=44)	-1.25 (2.53)
Wrist and MCP Aggregate Score, Baseline AV (n=56)	9.36 (4.49)
Wrist and MCP Aggregate Score, Week 2 (n=46)	-0.54 (2.67)
Wrist and MCP Aggregate Score, Week 4 (n=50)	-0.74 (2.62)
Wrist and MCP Aggregate Score, Week 12 (n=51)	-1.33 (3.58)
Wrist and MCP Aggregate Score, Week 24 (n=50)	-2.24 (3.54)
Wrist and MCP Aggregate Score, Week 48 (n=47)	-2.49 (3.59)

8. Secondary Outcome

Title	Change From Baseline to Weeks 2, 4, 12, 24, and 48 in Number of Bones With Erosion in the Wrist and MCP Joints
Description	Erosion was evaluated at 15 sites in the wrist and 8 sites in the MCP joints. Bone erosion was scored on a scale of 0 to 10, where 0 represented no bone erosion and each 1-point increase reflected up to a 10% increase in extent of erosion. The number of bones with erosion was taken as the count of joints with a bone erosion score greater than or equal to (≥) 1. Baseline AV and changes from Baseline to Weeks 2, 4, 12, 24, and 48 were averaged among all participants, where negative changes indicated improvement in erosion.
Time Frame	Baseline and Weeks 2, 4, 12, 24, 48

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	56
Baseline AV (n=56)	8.07 (4.71)
Week 2 (n=46)	-0.26 (1.16)
Week 4 (n=50)	-0.16 (1.04)
Week 12 (n=51)	-0.14 (1.61)
Week 24 (n=50)	-0.06 (1.82)
Week 48 (n=48)	-0.04 (2.81)

9. Secondary Outcome

Title	Change From Baseline to Weeks 2, 4, 12, 24, and 48 in Erosion of the Wrist and MCP Joints According to RAMRIS Score
Description	Erosion was evaluated at 15 sites in the wrist and 8 sites in the MCP joints. Bone erosion was scored on a scale of 0 to 10, where 0 represented no bone erosion and each 1-point increase reflected up to 10% increase in extent of erosion. Global RAMRIS scores were calculated as the sum of all joint sites for the wrist (range, 0 to 150) and MCP joints (range, 0 to 80). Aggregate wrist and MCP joint scores could range from 0 to 230 points. Baseline AV and changes from Baseline to Weeks 2, 4, 12, 24, and 48 were averaged among all participants, where negative changes indicated improvement in erosion.
Time Frame	Baseline and Weeks 2, 4, 12, 24, 48

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	56
Wrist Score, Baseline AV (n=56)	7.32 (5.34)
Wrist Score, Week 2 (n=46)	-0.24 (1.14)
Wrist Score, Week 4 (n=50)	-0.16 (1.11)
Wrist Score, Week 12 (n=51)	0.08 (1.40)
Wrist Score, Week 24 (n=50)	0.28 (3.16)
Wrist Score, Week 48 (n=47)	0.34 (3.67)
MCP Score, Baseline AV (n=54)	4.26 (7.42)
MCP Score, Week 2 (n=41)	-0.02 (0.88)
MCP Score, Week 4 (n=47)	-0.04 (0.66)
MCP Score, Week 12 (n=45)	0.04 (1.19)
MCP Score, Week 24 (n=46)	-0.07 (1.65)
MCP Score, Week 48 (n=44)	0.09 (1.18)
Wrist and MCP Aggregate Score, Baseline AV (n=56)	11.43 (9.98)
Wrist and MCP Aggregate Score, Week 2 (n=46)	-0.39 (1.86)
Wrist and MCP Aggregate Score, Week 4 (n=50)	-0.24 (1.55)
Wrist and MCP Aggregate Score, Week 12 (n=51)	-0.41 (3.14)
Wrist and MCP Aggregate Score, Week 24 (n=50)	-0.18 (4.77)
Wrist and MCP Aggregate Score, Week 48 (n=47)	0.36 (4.17)

10. Secondary Outcome

Title	Change From Baseline to Weeks 2, 4, 12, 24, and 48 in Number of Bones With Bone Marrow Edema in the Wrist and MCP Joints
Description	Edema was evaluated at 15 sites in the wrist and 8 sites in the MCP joints. Bone edema was scored on a scale of 0 to 3, where 0 represented no bone edema and each 1-point increase reflected one-third increase in extent of edema. The number of bones with edema was taken as the count of joints with a bone edema score greater than or equal to (≥) 1. Baseline AV and changes from Baseline to Weeks 2, 4, 12, 24, and 48 were averaged among all participants, where negative changes indicated improvement in edema.
Time Frame	Baseline and Weeks 2, 4, 12, 24, 48

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	56
Baseline AV (n=56)	7.91 (6.27)
Week 2 (n=46)	-0.57 (3.46)
Week 4 (n=50)	-0.78 (3.51)
Week 12 (n=51)	-1.80 (3.98)
Week 24 (n=50)	-2.56 (4.13)
Week 48 (n=48)	-3.56 (5.07)

11. Secondary Outcome

Title	Change From Baseline to Weeks 2, 4, 12, 24, and 48 in Bone Marrow Edema of the Wrist and MCP Joints According to RAMRIS Score
Description	Edema was evaluated at 15 sites in the wrist and 8 sites in the MCP joints. Bone edema was scored on a scale of 0 to 3, where 0 represented no bone edema and each 1-point increase reflected one-third increase in extent of edema. Global RAMRIS scores were calculated as the sum of all joint sites for the wrist (range, 0 to 45) and MCP joints (range, 0 to 24). Aggregate wrist and MCP joint scores could range from 0 to 69 points. Baseline AV and changes from Baseline to Weeks 2, 4, 12, 24, and 48 were averaged among all participants, where negative changes indicated improvement in edema.
Time Frame	Baseline and Weeks 2, 4, 12, 24, 48

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	56
Wrist Score, Baseline AV (n=56)	13.11 (12.88)
Wrist Score, Week 2 (n=46)	-0.61 (6.23)
Wrist Score, Week 4 (n=50)	-0.68 (5.87)
Wrist Score, Week 12 (n=51)	-3.02 (8.55)
Wrist Score, Week 24 (n=50)	-4.94 (10.80)
Wrist Score, Week 48 (n=47)	-6.45 (11.90)
MCP Score, Baseline AV (n=54)	3.17 (4.64)
MCP Score, Week 2 (n=41)	-0.32 (3.66)
MCP Score, Week 4 (n=47)	-0.89 (4.17)
MCP Score, Week 12 (n=45)	-1.47 (4.01)
MCP Score, Week 24 (n=46)	-1.70 (3.35)
MCP Score, Week 48 (n=44)	-1.98 (4.13)
Wrist and MCP Aggregate Score, Baseline AV (n=56)	16.16 (15.20)
Wrist and MCP Aggregate Score, Week 2 (n=46)	-0.89 (7.71)
Wrist and MCP Aggregate Score, Week 4 (n=50)	-1.52 (7.90)
Wrist and MCP Aggregate Score, Week 12 (n=51)	-4.67 (9.29)
Wrist and MCP Aggregate Score, Week 24 (n=50)	-6.70 (10.98)
Wrist and MCP Aggregate Score, Week 48 (n=47)	-8.30 (13.06)

12. Secondary Outcome

Title	Change From Baseline to Weeks 24 and 48 in Total Modified Sharp Score (TMSS), Erosion Score (ES), and Joint Space Narrowing Score (JSNS)
Description	The TMSS was calculated as the sum of ES and JSNS and ranged from 0 to 202. The ES was taken as the sum of joint scores collected for 14 joints in each hand (individually scored from 0 to 7) and ranged from 0 to 98 for both hands. The JSNS was the sum of joint scores collected for 13 joints in each hand (individually scored from 0 to 8) and ranged from 0 to 104 for both hands. Scores of 0 reflected no change, while higher scores reflected increased disease activity. Baseline AV and changes from Baseline to Weeks 24 and 48 were averaged among all participants, where negative changes indicated improvement in disease activity.
Time Frame	Baseline and Weeks 24, 48

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	55
TMSS, Baseline AV (n=55)	18.25 (26.37)
TMSS, Week 24 (n=46)	0.41 (3.03)
TMSS, Week 48 (n=47)	1.46 (5.66)
ES, Baseline AV (n=55)	4.78 (11.85)
ES, Week 24 (n=46)	0.05 (0.60)
ES, Week 48 (n=47)	0.31 (1.07)
JSNS, Baseline AV (n=55)	13.46 (17.39)
JSNS, Week 24 (n=46)	0.36 (3.00)
JSNS, Week 48 (n=47)	1.15 (5.42)

13. Secondary Outcome

Title	Change From Baseline to Weeks 2, 4, 12, 24, and 48 in Ritchie Articular Index Score
Description	The Ritchie Articular Index was scored on a scale of 0 to 3, according to the grades of tenderness in each of 26 assessed joints. The total score was taken as the sum of joint scores and ranged from 0 to 78. Scores of 0 reflected no tenderness, while higher scores reflected increased tenderness. Baseline AV and changes from Baseline to Weeks 2, 4, 12, 24, and 48 were averaged among all participants, where negative changes indicated improvement in joint tenderness.
Time Frame	Baseline and Weeks 2, 4, 12, 24, 48

Outcome Measure Data

Analysis Population Description

ITT Population. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	58
Baseline AV (n=58)	16.69 (7.50)
Week 2 (n=53)	-4.85 (5.37)
Week 4 (n=54)	-7.06 (6.50)
Week 12 (n=52)	-9.37 (6.65)
Week 24 (n=53)	-11.60 (6.71)
Week 48 (n=54)	-12.09 (6.95)

14. Secondary Outcome

Title	Change From Baseline to Weeks 2, 4, 12, 24, and 48 in Perceived Pain According to Visual Analog Scale (VAS) Score
Description	Perceived pain was assessed on a 0- to 100-millimeter (mm) VAS, where the distance from 0 mm represented the participant's self evaluation of pain (0 mm = no pain, 100 mm = maximum pain). Baseline AV and changes from Baseline to Weeks 2, 4, 12, 24, and 48 were averaged among all participants, where negative changes indicated a decrease in perceived pain.
Time Frame	Baseline and Weeks 2, 4, 12, 24, 48

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	54
Baseline AV (n=54)	57.69 (24.07)
Week 2 (n=50)	-18.56 (20.73)
Week 4 (n=51)	-20.57 (22.44)
Week 12 (n=52)	-32.75 (29.00)
Week 24 (n=50)	-35.36 (24.62)
Week 48 (n=50)	-39.44 (25.26)

15. Secondary Outcome

Title	Change From Baseline to Weeks 2, 4, 12, 24, and 48 in Perceived General Health According to VAS Score
Description	Global assessment of disease activity was performed using a 0- to 100-mm VAS, where the distance from 0 mm represented the investigator's evaluation or the participant's self evaluation of disease activity (0 mm = no disease activity, 100 mm = maximum disease activity). Baseline AV and changes from Baseline to Weeks 2, 4, 12, 24, and 48 were averaged among all participants, where negative changes indicated improvement in disease activity.
Time Frame	Baseline and Weeks 2, 4, 12, 24, 48

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	55
Participant Evaluation, Baseline AV (n=55)	59.51 (23.32)
Participant Evaluation, Week 2 (n=50)	-19.58 (20.75)
Participant Evaluation, Week 4 (n=52)	-19.73 (23.46)
Participant Evaluation, Week 12 (n=53)	-32.64 (28.59)
Participant Evaluation, Week 24 (n=51)	-36.55 (23.84)
Participant Evaluation, Week 48 (n=51)	-40.41 (25.69)
Investigator Evaluation, Baseline AV (n=54)	58.89 (16.26)
Investigator Evaluation, Week 2 (n=47)	-19.21 (16.71)
Investigator Evaluation, Week 4 (n=51)	-27.55 (20.49)
Investigator Evaluation, Week 12 (n=51)	-37.61 (21.63)
Investigator Evaluation, Week 24 (n=50)	-43.94 (19.55)
Investigator Evaluation, Week 48 (n=50)	-44.72 (18.98)

16. Secondary Outcome

Title	Change From Baseline to Weeks 2, 4, 12, 24, and 48 in Health Assessment Questionnaire Disability Index (HAQ-DI) Score
Description	The HAQ-DI assessed 20 items in eight functional activity domains including dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. Each item was scored on a scale of 0 to 3, where 0 represented activities performed without difficulty and 3 represented inability to perform activities alone. The total score was calculated as an average of all item scores, and thus also ranged from 0 to 3. Baseline AV and changes from Baseline to Weeks 2, 4, 12, 24, and 48 were averaged among all participants, where negative changes indicated an increase in ability to perform activities independently.
Time Frame	Baseline and Weeks 2, 4, 12, 24, 48

Outcome Measure Data

Analysis Population Description

ITT Population. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	58
Baseline AV (n=58)	1.33 (0.78)
Week 2 (n=52)	-0.34 (0.51)
Week 4 (n=53)	-0.35 (0.49)
Week 12 (n=54)	-0.52 (0.68)
Week 24 (n=53)	-0.61 (0.58)
Week 48 (n=54)	-0.67 (0.61)

17. Secondary Outcome

Title	Change From Baseline to Weeks 2, 4, 12, 24, and 48 in Disease Activity Score of 28 Joints (DAS28) Score
Description	The DAS28 was derived from assessments of C-reactive protein (CRP), tender joint count (TJC), swollen joint count (SJC), and general health according to 100-mm VAS. DAS28 scores were calculated as [0.56 × square root of TJC] plus (+) [0.28 × square root of SJC] + [0.36 × natural log (CRP + 1)] + [0.014 × VAS] + 0.96. TJC was defined as the number of painful joints and SJC was defined as the number of swollen joints, each assessed on 28 joints. CRP was measured in milligrams per deciliter (mg/dL). DAS28 scores could range from 0 to 10, where higher scores represented higher disease activity. Baseline AV and changes from Baseline to Weeks 2, 4, 12, 24, and 48 were averaged among all participants, where negative changes indicated an improvement in disease activity.
Time Frame	Baseline and Weeks 2, 4, 12, 24, 48

Outcome Measure Data

Analysis Population Description

ITT Population. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	58
Baseline AV (n=58)	5.44 (0.90)
Week 2 (n=50)	-1.22 (0.88)
Week 4 (n=53)	-1.62 (1.05)
Week 12 (n=53)	-2.29 (1.31)
Week 24 (n=53)	-2.88 (1.17)
Week 48 (n=53)	-3.07 (1.27)

18. Secondary Outcome

Title	Change From Baseline to Weeks 2, 4, 12, 24, and 48 in Vascular Endothelial Growth Factor (VEGF) Concentration
Description	Level of VEGF was measured in picograms per milliliter (pg/mL). Baseline AV and changes from Baseline to Weeks 2, 4, 12, 24, and 48 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4, 12, 24, 48

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	53
Baseline AV (n=53)	154.37 (130.97)
Week 2 (n=45)	-53.06 (145.81)
Week 4 (n=48)	-63.61 (121.55)
Week 12 (n=47)	-36.33 (189.04)
Week 24 (n=45)	-66.10 (139.38)
Week 48 (n=45)	-29.35 (183.46)

19. Secondary Outcome

Title	Change From Baseline to Weeks 2, 4, 12, 24, and 48 in Erythrocyte Sedimentation Rate (ESR)
Description	ESR was measured in millimeters per hour (mm/h). Baseline AV and changes from Baseline to Weeks 2, 4, 12, 24, and 48 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4, 12, 24, 48

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	56
Baseline AV (n=56)	37.39 (23.79)
Week 2 (n=47)	-27.30 (20.08)
Week 4 (n=52)	-27.63 (21.17)
Week 12 (n=51)	-28.75 (23.00)
Week 24 (n=50)	-30.58 (22.96)
Week 48 (n=51)	-27.22 (21.79)

20. Secondary Outcome

Title	Change From Baseline to Weeks 2, 4, 12, 24, and 48 in High-Sensitivity C-Reactive Protein (hsCRP) Concentration
Description	Level of hsCRP was measured in mg/dL. Baseline AV and changes from Baseline to Weeks 2, 4, 12, 24, and 48 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4, 12, 24, 48

Outcome Measure Data

Analysis Population Description

ITT Population. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	58
Baseline AV (n=58)	14.43 (20.46)
Week 2 (n=50)	-13.44 (21.56)
Week 4 (n=53)	-11.96 (18.23)
Week 12 (n=55)	-11.56 (22.51)
Week 24 (n=53)	-13.43 (21.10)
Week 48 (n=53)	-10.49 (12.31)

21. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in Soluble Interleukin-6 Receptor (sIL6R) Level
Description	Level of sIL6R was measured in pg/mL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	57
Baseline AV (n=57)	45270.8 (19965.0)
Week 2 (n=44)	332597.2 (264433.0)
Week 4 (n=50)	303037.2 (253261.4)

22. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in Messenger Ribonucleic Acid (mRNA) for Interleukin (IL)-17 (2^Delta Cycle Threshold [ΔCt]) Level
Description	Level of mRNA for IL-17 (2^ΔCt) was quantified by polymerase chain reaction (PCR). Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	51
Baseline AV (n=51)	0.0 (0.0)
Week 2 (n=37)	0.0 (0.0)
Week 4 (n=44)	0.0 (0.0)

23. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in mRNA for IL-23 Receptor (2^ΔCt) Level
Description	Level of mRNA for IL-23 receptor (2^ΔCt) was quantified by PCR. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	41
Baseline AV (n=41)	0.224 (0.415)
Week 2 (n=31)	-0.007 (0.268)
Week 4 (n=35)	0.015 (0.495)

24. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in mRNA for RAR-Related Orphan Receptor (ROR)-γT (2^ΔCt) Level
Description	Level of ROR-γT (2^ΔCt) was quantified by PCR. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	51
Baseline AV (n=51)	0.083 (0.269)
Week 2 (n=37)	-0.027 (0.259)
Week 4 (n=44)	-0.004 (0.310)

25. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in mRNA for Forkhead Box Protein (FOXP) 3 (2^ΔCt) Level
Description	Level of mRNA for FOXP3 (2^ΔCt) was quantified by PCR. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	51
Baseline AV (n=51)	1.035 (2.509)
Week 2 (n=37)	-0.315 (1.446)
Week 4 (n=44)	-0.059 (1.615)

26. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in Cluster of Differentiation (CD) 4-Positive Cells as a Percentage of Peripheral Blood Mononuclear Cells (PBMCs)
Description	The intensity of CD4-positive cell infiltration was expressed as the percentage of PBMCs. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	51
Baseline AV (n=51)	56.15 (12.63)
Week 2 (n=29)	-1.47 (13.64)
Week 4 (n=45)	0.77 (8.97)

27. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in CD4 Mean Intensity of Fluorescence
Description	The mean fluorescence intensity of CD4-positive cells was measured by flow cytometry. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	51
Baseline AV (n=51)	6970.94 (2725.05)
Week 2 (n=29)	464.04 (3341.91)
Week 4 (n=45)	-1139.29 (3024.58)

28. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in CD25-Positive Cells as a Percentage of PBMCs
Description	The intensity of CD25-positive cell infiltration was expressed as the percentage of PBMCs. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	51
Baseline AV (n=51)	7.27 (4.92)
Week 2 (n=28)	-0.95 (6.54)
Week 4 (n=45)	0.04 (5.63)

29. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in CD25 Mean Intensity of Fluorescence
Description	The mean fluorescence intensity of CD25-positive cells was measured by flow cytometry. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	51
Baseline AV (n=51)	2326.25 (923.68)
Week 2 (n=28)	74.76 (1850.13)
Week 4 (n=45)	162.27 (632.62)

30. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in CD45 "RO" Isoform (RO)-Positive Cells as a Percentage of PBMCs
Description	The intensity of CD45RO-positive cell infiltration was expressed as the percentage of PBMCs. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	50
Baseline AV (n=50)	37.16 (11.50)
Week 2 (n=23)	1.77 (13.88)
Week 4 (n=45)	3.06 (11.65)

31. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in CD45RO Mean Intensity of Fluorescence
Description	The mean fluorescence intensity of CD45RO-positive cells was measured by flow cytometry. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	49
Baseline AV (n=49)	5138.47 (2184.11)
Week 2 (n=22)	-1779.59 (2088.51)
Week 4 (n=44)	-131.75 (1908.48)

32. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in Cysteine-Cysteine Chemokine Receptor (CCR) 6-Positive Cells as a Percentage of PBMCs
Description	The intensity of CCR6-positive cell infiltration was expressed as the percentage of PBMCs. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	27
Baseline AV (n=27)	12.75 (6.40)
Week 2 (n=19)	2.34 (7.06)
Week 4 (n=16)	3.09 (6.76)

33. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in CCR6 Mean Intensity of Fluorescence
Description	The mean fluorescence intensity of CCR6-positive cells was measured by flow cytometry. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	27
Baseline AV (n=27)	4651.85 (1211.33)
Week 2 (n=19)	291.63 (1820.02)
Week 4 (n=16)	376.56 (1306.58)

34. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in CCR4-Positive Cells as a Percentage of PBMCs
Description	The intensity of CCR4-positive cell infiltration was expressed as the percentage of PBMCs. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	27
Baseline AV (n=27)	11.79 (5.45)
Week 2 (n=19)	-1.64 (4.01)
Week 4 (n=16)	0.35 (3.11)

35. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in CCR4 Mean Intensity of Fluorescence
Description	The mean fluorescence intensity of CCR4-positive cells was measured by flow cytometry. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	27
Baseline AV (n=27)	2534.67 (570.00)
Week 2 (n=19)	262.95 (755.79)
Week 4 (n=16)	273.19 (687.01)

36. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in IL-23 Receptor p19 Subunit (IL-23Rp19)-Positive Cells as a Percentage of PBMCs
Description	The intensity of IL-23Rp19-positive cell infiltration was expressed as the percentage of PBMCs. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	27
Baseline AV (n=27)	1.10 (1.19)
Week 2 (n=19)	-0.32 (0.92)
Week 4 (n=16)	-0.34 (0.49)

37. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in IL-23Rp19 Mean Intensity of Fluorescence
Description	The mean fluorescence intensity of IL-23Rp19-positive cells was measured by flow cytometry. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	27
Baseline AV (n=27)	1416.30 (331.05)
Week 2 (n=19)	284.42 (1145.08)
Week 4 (n=16)	82.88 (552.61)

38. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in Regulatory T (Treg) Cells as a Percentage of PBMCs
Description	The intensity of Treg cell infiltration was expressed as the percentage of PBMCs. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	50
Baseline AV (n=50)	2.03 (1.02)
Week 2 (n=39)	-0.07 (0.86)
Week 4 (n=42)	0.35 (1.41)

39. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in Treg Cells as a Percentage of T Cells
Description	The intensity of Treg cell infiltration was expressed as the percentage of T cells. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	50
Baseline AV (n=50)	2.42 (1.18)
Week 2 (n=39)	-0.19 (0.98)
Week 4 (n=42)	0.44 (1.80)

40. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in Treg Cell Level
Description	The absolute number of Treg cells was expressed as cells per microliter (cells/mcL). Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	49
Baseline AV (n=49)	34.51 (18.35)
Week 2 (n=35)	1.25 (13.75)
Week 4 (n=42)	6.30 (34.60)

41. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in Helper T (Th) 17 Cells as a Percentage of PBMCs
Description	The intensity of Th17 cell infiltration was expressed as the percentage of PBMCs. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	27
Baseline AV (n=27)	0.024 (0.036)
Week 2 (n=18)	0.006 (0.059)
Week 4 (n=16)	-0.002 (0.064)

42. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in Th17 Cells as a Percentage of T Cells
Description	The intensity of Th17 cell infiltration was expressed as the percentage of T cells. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	27
Baseline AV (n=27)	0.031 (0.049)
Week 2 (n=18)	-0.003 (0.076)
Week 4 (n=16)	-0.007 (0.027)

43. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in Th17 Cell Level
Description	The absolute number of Th17 cells was expressed as cells/mcL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	27
Baseline AV (n=27)	0.295 (0.368)
Week 2 (n=18)	0.050 (0.344)
Week 4 (n=17)	-0.068 (0.288)

44. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in CD19-Positive Cells as a Percentage of PBMCs
Description	The intensity of CD19-positive cell infiltration was expressed as the percentage of PBMCs. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	49
Baseline AV (n=49)	8.40 (4.68)
Week 2 (n=1)	-4.80 (NA)
Week 4 (n=44)	-0.12 (6.39)

45. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in CD19 Mean Intensity of Fluorescence
Description	The mean fluorescence intensity of CD19-positive cells was measured by flow cytometry. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	49
Baseline AV (n=49)	19268.58 (5482.10)
Week 2 (n=1)	-3656.00 (NA)
Week 4 (n=44)	251.34 (5251.35)

46. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in CD24-Positive Cells as a Percentage of PBMCs
Description	The intensity of CD24-positive cell infiltration was expressed as the percentage of PBMCs. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	49
Baseline AV (n=49)	8.02 (4.64)
Week 2 (n=1)	-4.90 (NA)
Week 4 (n=44)	-0.73 (6.21)

47. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in CD24 Mean Intensity of Fluorescence
Description	The mean fluorescence intensity of CD24-positive cells was measured by flow cytometry. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	49
Baseline AV (n=49)	3133.63 (1652.36)
Week 2 (n=1)	1015.00 (NA)
Week 4 (n=44)	436.05 (1827.22)

48. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in CD27-Positive Cells as a Percentage of PBMCs
Description	The intensity of CD27-positive cell infiltration was expressed as the percentage of PBMCs. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	49
Baseline AV (n=49)	57.51 (16.48)
Week 2 (n=1)	-12.40 (NA)
Week 4 (n=44)	1.44 (12.22)

49. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in CD27 Mean Intensity of Fluorescence
Description	The mean fluorescence intensity of CD27-positive cells was measured by flow cytometry. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	49
Baseline AV (n=49)	1288.10 (302.90)
Week 2 (n=1)	-349.00 (NA)
Week 4 (n=44)	-53.98 (390.89)

50. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in CD38-Positive Cells as a Percentage of PBMCs
Description	The intensity of CD38-positive cell infiltration was expressed as the percentage of PBMCs. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	49
Baseline AV (n=49)	49.51 (11.51)
Week 2 (n=1)	-4.30 (NA)
Week 4 (n=44)	-0.78 (10.87)

51. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in CD38 Mean Intensity of Fluorescence
Description	The mean fluorescence intensity of CD38-positive cells was measured by flow cytometry. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	49
Baseline AV (n=49)	5746.98 (2082.63)
Week 2 (n=1)	-193.00 (NA)
Week 4 (n=44)	162.66 (1602.09)

52. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in Immunoglobulin (Ig) M-Positive Cells as a Percentage of PBMCs
Description	The intensity of IgM-positive cell infiltration was expressed as the percentage of PBMCs. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	49
Baseline AV (n=49)	17.06 (14.50)
Week 2 (n=1)	-3.60 (NA)
Week 4 (n=44)	1.19 (11.61)

53. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in IgM Mean Intensity of Fluorescence
Description	The mean fluorescence intensity of IgM-positive cells was measured by flow cytometry. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	49
Baseline AV (n=49)	15545.94 (7231.80)
Week 2 (n=1)	-10381.0 (NA)
Week 4 (n=44)	-56.45 (5681.03)

54. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in Mature B Cells as a Percentage of PBMCs
Description	The intensity of mature B cell infiltration was expressed as the percentage of PBMCs. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	49
Baseline AV (n=49)	4.72 (3.56)
Week 2 (n=1)	-3.40 (NA)
Week 4 (n=44)	-0.35 (4.24)

55. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in Mature B Cells as a Percentage of B Cells
Description	The intensity of mature B cell infiltration was expressed as the percentage of B cells. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	49
Baseline AV (n=49)	48.58 (14.72)
Week 2 (n=1)	-9.40 (NA)
Week 4 (n=44)	-0.11 (13.79)

56. Secondary Outcome

Title	Change From Baseline to Week 4 in Mature B Cell Level
Description	The absolute number of mature B cells was expressed as cells/mcL. Baseline AV and change from Baseline to Week 4 were averaged among all participants.
Time Frame	Baseline and Week 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	47
Baseline AV (n=47)	78.27 (73.37)
Week 4 (n=42)	2.29 (74.72)

57. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in Memory B Cells as a Percentage of PBMCs
Description	The intensity of memory B cell infiltration was expressed as the percentage of PBMCs. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	49
Baseline AV (n=49)	1.49 (1.56)
Week 2 (n=1)	-0.90 (NA)
Week 4 (n=44)	0.13 (1.28)

58. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in Memory B Cells as a Percentage of B Cells
Description	The intensity of memory B cell infiltration was expressed as the percentage of B cells. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	49
Baseline AV (n=49)	18.95 (13.36)
Week 2 (n=1)	4.30 (NA)
Week 4 (n=44)	0.62 (10.87)

59. Secondary Outcome

Title	Change From Baseline to Week 4 in Memory B Cell Level
Description	The absolute number of memory B cells was expressed as cells/mcL. Baseline AV and change from Baseline to Week 4 were averaged among all participants.
Time Frame	Baseline and Week 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	47
Baseline AV (n=47)	29.29 (40.81)
Week 4 (n=42)	2.85 (37.60)

60. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in Transitional B Cells as a Percentage of PBMCs
Description	The intensity of transitional B cell infiltration was expressed as the percentage of PBMCs. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	49
Baseline AV (n=49)	0.58 (1.12)
Week 2 (n=1)	0.00 (NA)
Week 4 (n=44)	-0.22 (1.21)

61. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in Transitional B Cells as a Percentage of B Cells
Description	The intensity of transitional B cell infiltration was expressed as the percentage of B cells. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	49
Baseline AV (n=49)	5.26 (5.61)
Week 2 (n=1)	5.80 (NA)
Week 4 (n=44)	-1.09 (4.54)

62. Secondary Outcome

Title	Change From Baseline to Week 4 in Transitional B Cell Level
Description	The absolute number of transitional B cells was expressed as cells/mcL. Baseline AV and change from Baseline to Week 4 were averaged among all participants.
Time Frame	Baseline and Week 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	47
Baseline AV (n=47)	6.70 (7.79)
Week 4 (n=42)	-0.62 (7.51)

63. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in Plasma B Cells as a Percentage of PBMCs
Description	The intensity of plasma B cell infiltration was expressed as the percentage of PBMCs. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	49
Baseline AV (n=49)	0.22 (0.57)
Week 2 (n=1)	0.00 (NA)
Week 4 (n=44)	-0.08 (0.60)

64. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in Plasma B Cells as a Percentage of B Cells
Description	The intensity of plasma B cell infiltration was expressed as the percentage of B cells. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	49
Baseline AV (n=49)	1.52 (4.54)
Week 2 (n=1)	-0.20 (NA)
Week 4 (n=44)	-0.06 (5.77)

65. Secondary Outcome

Title	Change From Baseline to Week 4 in Plasma B Cell Level
Description	The absolute number of plasma B cells was expressed as cells/mcL. Baseline AV and change from Baseline to Week 4 were averaged among all participants.
Time Frame	Baseline and Week 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	47
Baseline AV (n=47)	3.13 (6.50)
Week 4 (n=42)	-1.11 (6.31)

66. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in Th17 Cysteine-Cysteine Chemokine Ligand (CCL) 20 Level
Description	Level of Th17CCL20 was measured in pg/mL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	57
Baseline AV (n=57)	35.03 (69.50)
Week 2 (n=46)	2.57 (20.72)
Week 4 (n=52)	-2.65 (23.18)

67. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in Th17CCL17 Level
Description	Level of Th17CCL20 was measured in pg/mL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	56
Baseline AV (n=56)	456.02 (404.17)
Week 2 (n=45)	119.58 (453.39)
Week 4 (n=51)	75.84 (333.43)

68. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in B Cell-Attracting Chemokine (BCA) Level
Description	Level of BCA was measured in pg/mL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	56
Baseline AV (n=56)	122.28 (87.48)
Week 2 (n=45)	-21.37 (70.40)
Week 4 (n=51)	-18.26 (103.62)

69. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in Stromal Cell-Derived Factor (SDF) 1 Level
Description	Level of SDF1 was measured in pg/mL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	57
Baseline AV (n=57)	2151.47 (1133.79)
Week 2 (n=46)	-1.85 (343.10)
Week 4 (n=52)	-26.46 (390.80)

70. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in B Cell-Activating Factor (BAFF) Level
Description	Level of BAFF was measured in pg/mL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	57
Baseline AV (n=57)	802.98 (317.98)
Week 2 (n=45)	28.04 (217.89)
Week 4 (n=52)	36.17 (223.64)

71. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in A Proliferation-Inducing Ligand (APRIL) Level
Description	Level of APRIL was measured in pg/mL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	57
Baseline AV (n=57)	6807.49 (11178.42)
Week 2 (n=45)	-816.13 (4036.61)
Week 4 (n=51)	7.82 (3843.69)

72. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in Tumor Necrosis Factor (TNF)-α Level
Description	Level of TNF-α was measured in pg/mL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	55
Baseline AV (n=55)	2.285 (4.234)
Week 2 (n=42)	0.077 (1.228)
Week 4 (n=46)	0.254 (0.978)

73. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in IL-1β Level
Description	Level of IL-1β was measured in pg/mL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	37
Baseline AV (n=37)	0.699 (0.692)
Week 2 (n=27)	-0.160 (0.598)
Week 4 (n=31)	-0.243 (0.620)

74. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in IL-17 Level
Description	Level of IL-17 was measured in pg/mL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	57
Baseline AV (n=57)	15.00 (0.00)
Week 2 (n=47)	0.00 (0.00)
Week 4 (n=52)	0.00 (0.00)

75. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in Monocyte Chemoattractant Protein (MCaP)-1 Level
Description	Level of MCaP-1 was measured in pg/mL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	57
Baseline AV (n=57)	343.86 (283.29)
Week 2 (n=47)	22.70 (143.82)
Week 4 (n=51)	-33.20 (133.52)

76. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in Osteocalcin Level
Description	Level of osteocalcin was measured in pg/mL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	57
Baseline AV (n=57)	14069.60 (8770.17)
Week 2 (n=47)	-616.34 (6899.51)
Week 4 (n=52)	-99.00 (6938.56)

77. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in Type I Collagen N-Propeptide Level
Description	Level of Type I collagen N-propeptide was measured in pg/mL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	57
Baseline AV (n=57)	7731.89 (4625.23)
Week 2 (n=46)	842.65 (4318.91)
Week 4 (n=51)	-576.49 (4108.27)

78. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in C-Terminal Telopeptide (CTX)-1 Level
Description	Level of CTX-1 was measured in pg/mL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	57
Baseline AV (n=57)	487.28 (248.61)
Week 2 (n=48)	43.33 (193.11)
Week 4 (n=50)	48.80 (233.25)

79. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in Type I Collagen C-Terminal Telopeptide (ICTP) Level
Description	Level of ICTP was measured in pg/mL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	57
Baseline AV (n=57)	6381.12 (2456.54)
Week 2 (n=48)	306.60 (1568.45)
Week 4 (n=51)	193.25 (1657.43)

80. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in Type II Collagen N-Propeptide (PIIANP) Level
Description	Level of PIIANP was measured in pg/mL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	57
Baseline AV (n=57)	1329158 (908163.5)
Week 2 (n=47)	-37518.8 (1008994)
Week 4 (n=51)	-69799.1 (673406.7)

81. Secondary Outcome

Title	Change From Baseline to Weeks 2 and 4 in Type II Collagen Helical Peptide (HELIX-II) Level
Description	Level of HELIX-II was measured in pg/mL. Baseline AV and changes from Baseline to Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	57
Baseline AV (n=57)	2521.12 (1960.76)
Week 2 (n=48)	126.02 (1480.97)
Week 4 (n=51)	-78.29 (1586.43)

82. Secondary Outcome

Title	Change From Baseline to Weeks 2, 4, 12, 24, and 48 in Hemoglobin (Hb) Concentration
Description	Level of Hb was measured in grams per liter (g/L). Baseline AV and changes from Baseline to Weeks 2, 4, 12, 24, and 48 were averaged among all participants.
Time Frame	Baseline and Weeks 2, 4, 12, 24, 48

Outcome Measure Data

Analysis Population Description

ITT Population. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	58
Baseline AV (n=58)	128.28 (12.10)
Week 2 (n=50)	3.86 (5.87)
Week 4 (n=54)	2.09 (5.35)
Week 12 (n=55)	4.31 (9.13)
Week 24 (n=53)	6.23 (8.99)
Week 48 (n=53)	7.17 (8.28)

83. Secondary Outcome

Title	Change From Baseline to Day 2 and Weeks 2 and 4 in Soluble Transferrin Receptor (STR) Concentration
Description	Level of STR was measured in pg/mL. Baseline AV and changes from Baseline to Day 2 and Weeks 2 and 4 were averaged among all participants.
Time Frame	Baseline; Day 2; and Weeks 2, 4

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	57
Baseline AV (n=57)	4536413 (1336641)
Day 2 (n=10)	-83532.0 (446321.3)
Week 2 (n=46)	15712.17 (821775.0)
Week 4 (n=52)	-89722.7 (959232.1)

84. Secondary Outcome

Title	Change From Baseline to Week 48 in Initial Rate of Enhancement (IRE) by DYNAMIKA Software Analysis
Description	IRE was approximated by parametric mapping via DYNAMIKA software and expressed as change in relative signal intensity per second (ΔI/sec). The mean of three different slices was used in the determination of IRE. Each slice consisted of a two-dimensional (2D) sequence of images acquired from the same physical location at different time instances. Baseline AV and change from Baseline to Week 48 were averaged among all participants.
Time Frame	Baseline and Week 48

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	49
Baseline AV (n=49)	0.00503 (0.00371)
Week 48 (n=32)	-0.00246 (0.00363)

85. Secondary Outcome

Title	Change From Baseline to Week 48 in Maximum Enhancement (ME) by DYNAMIKA Software Analysis
Description	ME was approximated by parametric mapping via DYNAMIKA software and expressed as ratio of signal enhancement before and after contrast injection. The mean of three different slices was used in the determination of ME. Each slice consisted of a 2D sequence of images acquired from the same physical location at different time instances. Baseline AV and change from Baseline to Week 48 were averaged among all participants.
Time Frame	Baseline and Week 48

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	49
Baseline AV (n=49)	1.606 (0.422)
Week 48 (n=32)	-0.177 (0.416)

86. Secondary Outcome

Title	Change From Baseline to Week 48 in Number of Enhancing Voxels (Ntotal) by DYNAMIKA Software Analysis
Description	Ntotal was approximated using DYNAMIKA software. The sum of three different slices was used in the determination of Ntotal. Each slice consisted of a 2D sequence of images acquired from the same physical location at different time instances. Baseline AV and change from Baseline to Week 48 were averaged among all participants.
Time Frame	Baseline and Week 48

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	48
Baseline AV (n=48)	3155.69 (1677.22)
Week 48 (n=31)	-974.16 (1606.14)

87. Secondary Outcome

Title	Change From Baseline to Week 48 in Number of Persistent Enhancing Voxels (Npersistent) by DYNAMIKA Software Analysis
Description	Npersistent was approximated using DYNAMIKA software. The sum of three different slices was used in the determination of Npersistent. Each slice consisted of a 2D sequence of images acquired from the same physical location at different time instances. Baseline AV and change from Baseline to Week 48 were averaged among all participants.
Time Frame	Baseline and Week 48

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	49
Baseline AV (n=49)	182.04 (157.15)
Week 48 (n=32)	-0.53 (219.74)

88. Secondary Outcome

Title	Change From Baseline to Week 48 in Number of Plateau Enhancing Voxels (Nplateau) by DYNAMIKA Software Analysis
Description	Nplateau was approximated using DYNAMIKA software. The sum of three different slices was used in the determination of Nplateau. Each slice consisted of a 2D sequence of images acquired from the same physical location at different time instances. Baseline AV and change from Baseline to Week 48 were averaged among all participants.
Time Frame	Baseline and Week 48

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	49
Baseline AV (n=49)	1839.63 (994.07)
Week 48 (n=32)	-635.72 (1019.13)

89. Secondary Outcome

Title	Change From Baseline to Week 48 in Number of Washout Enhancing Voxels (Nwashout) by DYNAMIKA Software Analysis
Description	Nwashout was approximated using DYNAMIKA software. The sum of three different slices was used in the determination of Nwashout. Each slice consisted of a 2D sequence of images acquired from the same physical location at different time instances. Baseline AV and change from Baseline to Week 48 were averaged among all participants.
Time Frame	Baseline and Week 48

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	49
Baseline AV (n=49)	1167.16 (783.19)
Week 48 (n=32)	-358.25 (798.88)

90. Secondary Outcome

Title	Change From Baseline to Week 48 in Ntotal×IRE by DYNAMIKA Software Analysis
Description	Ntotal and IRE were approximated using DYNAMIKA software. The sum of three different slices was used in the determination of Ntotal. The mean of three different slices was used in the determination of IRE. Each slice consisted of a 2D sequence of images acquired from the same physical location at different time instances. Function of Ntotal×IRE was expressed as voxels times change in relative intensity per second (v*ΔI/sec). Baseline AV and change from Baseline to Week 48 were averaged among all participants.
Time Frame	Baseline and Week 48

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	48
Baseline AV (n=48)	6.01 (5.93)
Week 48 (n=31)	-4.84 (6.13)

91. Secondary Outcome

Title	Change From Baseline to Week 48 in Ntotal×ME by DYNAMIKA Software Analysis
Description	Ntotal and ME were approximated using DYNAMIKA software. The sum of three different slices was used in the determination of Ntotal. The mean of three different slices was used in the determination of ME. Each slice consisted of a 2D sequence of images acquired from the same physical location at different time instances. Function of NtotalME was expressed as voxels times ratio of signal intensity before and after contrast injection (v*ratio). Baseline AV and change from Baseline to Week 48 were averaged among all participants.
Time Frame	Baseline and Week 48

Outcome Measure Data

Analysis Population Description

ITT Population. The "Number of Participants Analyzed" reflects the total number of participants who contributed to the endpoint. The number of participants who contributed to the analysis at each timepoint (n) is shown in the table.

Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
Measure Participants	48
Baseline AV (n=48)	1882.40 (1267.48)
Week 48 (n=31)	-793.59 (1168.57)

Adverse Events

Time Frame	Baseline to Week 48
Adverse Event Reporting Description	Safety Population (same as ITT Population): All enrolled participants who received at least one dose of study drug.
Arm/Group Title	Tocilizumab in Active RA
Arm/Group Description	Participants with active RA received tocilizumab as 8 mg/kg via IV infusion every 4 weeks. A total of 12 infusions were given from Baseline to Week 44, and participants were assessed through Week 48.
All Cause Mortality
	Tocilizumab in Active RA
	Affected / at Risk (%)	# Events
Total	/ (NaN)
Serious Adverse Events
	Tocilizumab in Active RA
	Affected / at Risk (%)	# Events
Total	5/58 (8.6%)
Cardiac disorders
Tachycardia	1/58 (1.7%)
Injury, poisoning and procedural complications
Upper limb fracture	1/58 (1.7%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-hodgkin's lymphoma	1/58 (1.7%)
Renal and urinary disorders
Renal colic	1/58 (1.7%)
Vascular disorders
Hypertension	1/58 (1.7%)
Other (Not Including Serious) Adverse Events
	Tocilizumab in Active RA
	Affected / at Risk (%)	# Events
Total	50/58 (86.2%)
Blood and lymphatic system disorders
Anaemia	3/58 (5.2%)
Iron deficiency anaemia	1/58 (1.7%)
Leukopenia	2/58 (3.4%)
Neutropenia	8/58 (13.8%)
Splenomegaly	1/58 (1.7%)
Thrombocytopenia	1/58 (1.7%)
Cardiac disorders
Tachycardia	2/58 (3.4%)
Ear and labyrinth disorders
Tinnitus	2/58 (3.4%)
Vertigo	2/58 (3.4%)
Eye disorders
Eyelid oedema	1/58 (1.7%)
Xerophthalmia	1/58 (1.7%)
Gastrointestinal disorders
Abdominal pain lower	1/58 (1.7%)
Abdominal pain upper	2/58 (3.4%)
Aphthous stomatitis	1/58 (1.7%)
Colitis	1/58 (1.7%)
Constipation	1/58 (1.7%)
Diarrhoea	2/58 (3.4%)
Dysentery	1/58 (1.7%)
Dyspepsia	2/58 (3.4%)
Enteritis	1/58 (1.7%)
Gastroenteritis	1/58 (1.7%)
Gastrointestinal disorder	1/58 (1.7%)
Gastrooesophageal reflux disease	1/58 (1.7%)
Haematochezia	2/58 (3.4%)
Haemorrhoids	1/58 (1.7%)
Oropharyngeal pain	2/58 (3.4%)
Toothache	1/58 (1.7%)
General disorders
Asthenia	1/58 (1.7%)
Chest pain	2/58 (3.4%)
Face oedema	1/58 (1.7%)
Hyperpyrexia	1/58 (1.7%)
Pyrexia	3/58 (5.2%)
Swelling	1/58 (1.7%)
Hepatobiliary disorders
Hepatic steatosis	1/58 (1.7%)
Hypertransaminasaemia	1/58 (1.7%)
Infections and infestations
Bronchitis	5/58 (8.6%)
Cystitis	1/58 (1.7%)
Escherichia infection	2/58 (3.4%)
Gastroenteritis	1/58 (1.7%)
Helicobacter gastritis	1/58 (1.7%)
Herpes ophthalmic	1/58 (1.7%)
Herpes simplex	1/58 (1.7%)
Herpes virus infection	1/58 (1.7%)
Herpes zoster	1/58 (1.7%)
Influenza	5/58 (8.6%)
Labyrinthitis	1/58 (1.7%)
Localised infection	1/58 (1.7%)
Nail infection	1/58 (1.7%)
Nasopharyngitis	7/58 (12.1%)
Oral candidiasis	1/58 (1.7%)
Oral herpes	3/58 (5.2%)
Pharyngitis	3/58 (5.2%)
Tonsillitis	1/58 (1.7%)
Tracheitis	3/58 (5.2%)
Urinary tract infection	2/58 (3.4%)
Injury, poisoning and procedural complications
Eye injury	1/58 (1.7%)
Fracture	1/58 (1.7%)
Joint dislocation	1/58 (1.7%)
Limb injury	1/58 (1.7%)
Investigations
Alanine aminotransferase increased	3/58 (5.2%)
Blood cholesterol increased	3/58 (5.2%)
Blood phosphorus increased	1/58 (1.7%)
Blood triglycerides increased	8/58 (13.8%)
Eosinophil count increased	2/58 (3.4%)
Lipids increased	2/58 (3.4%)
Neutrophil count decreased	1/58 (1.7%)
Platelet count decreased	1/58 (1.7%)
Red blood cell sedimentation rate increased	1/58 (1.7%)
Transaminases increased	5/58 (8.6%)
White blood cell count decreased	1/58 (1.7%)
Metabolism and nutrition disorders
Hypercholesterolaemia	11/58 (19%)
Hypertriglyceridaemia	2/58 (3.4%)
Hypokalaemia	2/58 (3.4%)
Musculoskeletal and connective tissue disorders
Arthralgia	1/58 (1.7%)
Back pain	3/58 (5.2%)
Bursitis	1/58 (1.7%)
Muscle spasms	1/58 (1.7%)
Musculoskeletal chest pain	1/58 (1.7%)
Musculoskeletal pain	1/58 (1.7%)
Neck pain	1/58 (1.7%)
Osteoarthritis	1/58 (1.7%)
Systemic lupus erythematosus	1/58 (1.7%)
Nervous system disorders
Carpal tunnel syndrome	2/58 (3.4%)
Dysaesthesia	1/58 (1.7%)
Headache	1/58 (1.7%)
Paraesthesia	1/58 (1.7%)
Presyncope	1/58 (1.7%)
Restless legs syndrome	1/58 (1.7%)
Sciatica	1/58 (1.7%)
Psychiatric disorders
Anxiety	2/58 (3.4%)
Depression	2/58 (3.4%)
Reproductive system and breast disorders
Metrorrhagia	1/58 (1.7%)
Ovarian cyst	1/58 (1.7%)
Respiratory, thoracic and mediastinal disorders
Cough	6/58 (10.3%)
Dyspnoea	1/58 (1.7%)
Oropharyngeal pain	1/58 (1.7%)
Pneumonitis	1/58 (1.7%)
Productive cough	5/58 (8.6%)
Throat irritation	1/58 (1.7%)
Skin and subcutaneous tissue disorders
Eczema	1/58 (1.7%)
Erythema	1/58 (1.7%)
Papule	1/58 (1.7%)
Pruritus	2/58 (3.4%)
Rash	1/58 (1.7%)
Rash erythematous	3/58 (5.2%)
Skin burning sensation	1/58 (1.7%)
Skin lesion	1/58 (1.7%)
Urticaria	1/58 (1.7%)
Urticaria papular	1/58 (1.7%)
Vascular disorders
Flushing	1/58 (1.7%)
Syncope	1/58 (1.7%)
Hypertension	1/58 (1.7%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.